27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Novavax, Inc. (NASDAQ: NVAX) will launch a Phase 1 clinical trial of an Ebola vaccine candidate in December, the company said at a conference Sunday in Philadelphia.
Novavax gained 5 percent in Monday's session, trading recently at $5.36 per share.
Vice President of Vaccine Development Gale Smith said in a news release Monday that in pre-clinical models, its glycoprotein recombinant nanoparticle vaccine candidate produced antibody levels "well within ranges" thought to protect against Ebola in rodents and monkeys.
Separately at the conference, Novavax said its vaccine candidate for influenza among newborns, pediatrics and elderly, could also benefit pregnant women.
A Phase 2 clinical trial in 330 women of childbearing age showed the vaccine reduced infections by 50 percent, the company said.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!